Aromasin Market, By Application (Tumors, Cancers, Menopausal Diseases, Hormonal Therapy and Others), By Form (Solid, Liquid, and Powder) By End-User (Hospitals, Clinics, Medical Research Organizations and Others) – Global Industry Insights, Trends and Forecast, 2017-2025

Created On: Aug-2018
Report ID: IR183
Format: PDF

Aromasin which has a chemical name of exemestane acts as an aromatase inhibitor which reduces the production of estrogen in women’s postmenopausal. Aromasin helps to reduce the growth of breast cancer cells that occurs due to stimulation of hormone androgens. Thus, the growth of aromasin market is expected to propel due to growing cases of postmenopausal problems such as urogenital atrophy, vasomotor symptoms, osteoporosis, sexual problems, and others of women as it also helps in lowering the breast cancer hormones form recurrence. Aromasin as an aromatase inhibitor, was approved by U.S. Food and Drug Administration (FDA), in 2015, for the treatment of postmenopausal women detected with hormone receptor positive, and in metastatic or advanced stage of positive breast cancer. Hormone receptor positive breast cancer was earlier treated with tamoxifen, however the discovery of aromasin has resulted in successful treatment of hormone receptor positive breast cancer by suppressing the ovarian function. Hormonal therapy which is done after surgery is called as adjuvant hormonal therapy, which use aromasin to block entrance of estrogen into the breast cancer cells. Aromasin is a substitute for tamoxifen in adjuvant hormonal therapy which is expected to boost the aromasin market in the forecast period. The tamoxifen market had a market size of over US$ 650 million in 2017, thus substitution of tamoxifen by aromasin is expected to boom in the forecast period for the global aromasin market. Owing to these factors, the aromasin market is expected to propel during the forecast period.

Aromasin Market: Growth & Developments

The aromasin market is expected to be driven by the growing prevalence of women’s breast cancer cases in global economies. According to the World Cancer Research Fund International, in 2017, 12 million women were diagnosed with cancer with over 2.4 million cases of breast cancer which is due to various causes such as increase in alcohol consumption that releases acetaldehyde incurring DNA damage and others. Others factors that increase breast cancer according to World Cancer Research Fund International, is obesity or overweight in adulthood, aging between 18-30 years. Aromasin is expected to cover the global market due to rise in prices of tamoxifen in the market. According to the European Cancer Congress, in 2017, the cost of tamoxifen increased 10 times from 2012 to 2016 and coupled with adverse effects of tamoxifen such as pain in urination, anxiety and others, the aromasin market is expected to propel during the forecast period. Increasing number of non-government and government organizations has invested to identify additional applications of aromasin, which is expected to propel the global aromasin market growth. For instance, aromasin is an alternative to evista and tamoxifen, thus the guidelines from the American Society of Clinical Oncology (ASCO), suggest doctors to consider aromasin for the treatment of high-risk postmenopausal of women to reduce the risk for development and recurrence of cancer. However, certain factors which is expected to hamper the aromasin market are the side effects of aromasin such as hot flashes, insomnia, dizziness, and others are some of the common side effects of aromasin in women suffering from early-stage and advanced breast cancer.

Aromasin Market: Regional Insights

North America is expected to dominate the aromasin market throughout the forecast period from 2018 to 2025, and Asia Pacific is expected to be the fastest growing by CAGR. The North America market in expected to be driven owing to its high approval over tamoxifen which are used for treating or reducing breast cancer and their recurrence. According to the U.S. Breast Cancer Organization, in 2017, approximately 1 out of 8 women in the United States is accounted to develop invasive breast cancer which accounts to around 266,120 women who are diagnosed with breast cancer in 2017, in the United States. According to the World Cancer Research Fund, lower indices of income and environmental factors are expected to increase in the number of cancer populous across the globe. Owing to these factors the global aromasin market is expected to propel during the forecast period.

Various companies have adopted innovation in aromasin drug for the treatment of vulvar atrophy symptoms in or around the vagina such as dryness, burning and itching for patients suffering from positive hormone receptive breast cancer, by companies such as Pear Tree Pharmaceuticals. Major players operating in the field of aromasin market are Pfizer Inc., GLS Pharma Ltd., Celon Laboratories Ltd., Natco Pharma Limited, Cipla Ltd, Upsher-Smith Labs, Mylan Pharms Inc, and others.

Our Research Approach Includes
  •  Market Outlining
  •  Framing discussion guide
  •  Data Validation
  • Data Analysis
  •  Re-Validation and Finalization of Data
  •  Report Insights and Publishing
Our Research Approach Includes
  •  Market Outlining
  •  Framing discussion guide
  •  Data Validation
  • Data Analysis
  •  Re-Validation and Finalization of Data
  •  Report Insights and Publishing
Reach Out to us